U.S. pharma giant copyright scrapped two experimental weight loss drugs last calendar year—a after-every day capsule, lotiglipron, as a result of elevated liver enzymes plus a 2 times-each day tablet, danuglipron, resulting from potent Unintended effects—but CEO Albert Bourla has claimed the company is decided to “Perform and earn” in the w